Woodline Partners’s Krystal Biotech KRYS Stock Holding History

Woodline Partners’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56M	Hold	150,616	–	–	0.17%	153
2026 Q1	$38.9M	Hold	150,616	–	–	0.15%	183
2025 Q4	$37.1M	Hold	150,616	–	–	0.14%	182
2025 Q3	$26.6M	Hold	150,616	–	–	0.13%	219
2025 Q2	$20.7M	Sell	150,616 -71,427	-32%	-$10.5M	0.11%	277
2025 Q1	$40M	Buy	222,043 +941	+0.4%	+$158K	0.26%	117
2024 Q4	$34.6M	Buy	221,102 +41,287	+23%	+$7.32M	0.23%	134
2024 Q3	$32.7M	Sell	179,815 -112,103	-38%	-$21.6M	0.28%	116
2024 Q2	$53.6M	Buy	291,918 +16,463	+6%	+$2.76M	0.51%	50
2024 Q1	$49M	Sell	275,455 -206,524	-43%	-$28.7M	0.45%	59
2023 Q4	$59.8M	Buy	481,979 +160,035	+50%	+$17.7M	0.65%	37
2023 Q3	$37.3M	Buy	321,944 +277,721	+628%	+$33.9M	0.44%	53
2023 Q2	$5.19M	Buy	+44,223	New	+$4.52M	0.06%	282

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners's KRYS Position: Q2 2026 in Review

Woodline Partners held its Krystal Biotech (KRYS) position steady in Q2 2026 at 150,616 shares worth $56M. The position accounts for 0.17% of the portfolio, ranked #153.

Woodline Partners first reported a position in KRYS in Q2 2023 and has held it in 13 quarters since. The position peaked at $59.8M in Q4 2023. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Woodline Partners held 150,616 shares of Krystal Biotech worth $56M as of Q2 2026.
Woodline Partners left its Krystal Biotech share count unchanged in Q2 2026.
Krystal Biotech made up 0.17% of Woodline Partners's portfolio in Q2 2026, its #153 holding.
Woodline Partners first reported a position in Krystal Biotech in Q2 2023 and has held it in 13 quarters since.
Woodline Partners's Krystal Biotech position peaked at $59.8M in Q4 2023.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.